Her-2/neu Overexpression and Amplification in Uterine Papillary Serous Carcinoma
- 1 August 2004
- journal article
- gynecologic cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (15) , 3126-3132
- https://doi.org/10.1200/jco.2004.11.154
Abstract
Purpose Uterine papillary serous carcinoma (UPSC) is an aggressive subtype of endometrial cancer characterized by early metastasis, resistance to therapy, and a high mortality rate. Little is known...Keywords
This publication has 41 references indexed in Scilit:
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- Treatment of Uterine Papillary Serous Carcinoma with PaclitaxelGynecologic Oncology, 2001
- Is Uterine Papillary Serous Adenocarcinoma a Manifestation of the Hereditary Breast–Ovarian Cancer Syndrome?Gynecologic Oncology, 2000
- Determination of Her-2/Neu Status in Breast Carcinoma: Comparative Analysis of Immunohistochemistry and Fluorescent In Situ HybridizationLaboratory Investigation, 2000
- What Staging Surgery Should Be Performed on Patients with Uterine Papillary Serous Carcinoma?Gynecologic Oncology, 1999
- The Use of Paclitaxel and Platinum-Based Chemotherapy in Uterine Papillary Serous CarcinomaGynecologic Oncology, 1999
- FISH detection of HER-2/neu oncogene amplification in early onset breast cancerBreast Cancer Research and Treatment, 1996
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu OncogeneScience, 1985